Healthcare / BiotechnologyNasdaqCM
$12.93
-0.48 (-3.58%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-78.0M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$186M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-228.0%
↓Gross Margin
N/A
•Debt/Equity
0.85
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-1237.2%
FCF / Net income
0.67x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.4M · net income $-117.3M · FCF $-79.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $6.4M | $6.4M | $2.3M | — | — | $14.1M | $37.0M | $28.9M | — | — |
| Net Income | $-117.3M | $-117.3M | $-83.6M | $-81.2M | $-58.0M | $-84.7M | $-26.5M | $-18.7M | $-19.2M | $-20.2M |
| EBITDA | $-83.1M | $-83.1M | $-88.3M | $-80.9M | $-56.5M | — | — | — | — | — |
| EPS | — | — | -9.37 | -53.08 | -7.25 | — | — | — | — | — |
| Operating Margin | -1366.4% | -1366.4% | -4047.1% | — | — | -597.3% | -74.5% | -71.4% | — | — |
| Net Margin | -1834.5% | -1834.5% | -3680.4% | — | — | -602.0% | -71.7% | -64.8% | — | — |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.85 | 0.85 | 0.28 | 0.20 | -0.03 | — | — | — | — | — |
| Current Ratio | 8.13 | 8.13 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-79.1M | $-79.1M | $-78.0M | $-75.1M | $-58.9M | $-79.0M | $-51.9M | $33.2M | $-17.5M | $-16.5M |
| Returns | ||||||||||
| ROE | -228.0% | -228.0% | -52.1% | -47.8% | 58.6% | — | — | — | — | — |
| Valuation | ||||||||||
| P/B | 2.37 | 2.37 | 2.38 | 0.45 | — | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | 181.5% | 181.5% | — | — | — | -62.0% | 27.8% | — | — | — |
| EPS Growth | — | — | 82.3% | -631.9% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+13.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-9.37 → n/d
Residual
+13.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.